Moonwalk Biosciences Appoints VP of Biology and Translational Science and Announces Formation of Cardiometabolic Advisory Board
2024年8月19日 - 9:00PM
ビジネスワイヤ(英語)
- John Liles, Ph.D., joins Moonwalk’s leadership team as VP
Biology and Translational Science to lead the discovery and early
development of novel therapies for cardiometabolic diseases
- Advisory Board members bring world class expertise and insights
to support and guide Moonwalk’s research programs
Moonwalk Biosciences, an epigenetic biology and AI company,
announced today the appointment of John Liles, Ph.D., as VP Biology
and Translational Science, and the formation of a world class
Cardiometabolic Advisory Board. Dr. Liles brings deep experience as
a drug discovery biologist with proven success advancing novel
therapeutics from target discovery through IND for liver, kidney,
lung and cardiovascular diseases.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240819252856/en/
John Liles, Ph.D., VP Biology and
Translational Science, Moonwalk Biosciences. (Photo credit:
Moonwalk Biosciences)
In addition, a leading advisory board of scientific and clinical
experts in adipocyte and liver biology bring invaluable insights to
Moonwalk’s research programs and therapeutic development efforts to
address unmet needs in cardiometabolic disease.
“We are thrilled to welcome John to our team and announce the
formation of our cardiometabolic advisory board,” said Alex
Aravanis, M.D., Ph.D., Co-founder & CEO, Moonwalk Biosciences,
“John’s expertise in translating innovative therapeutics from
discovery through IND will accelerate our ambitious R&D
efforts.”
Dr. Liles brings more than 17 years of experience to Moonwalk,
most recently as Executive Director, Kidney Disease Research &
Strategy at Chinook Therapeutics (acquired by Novartis), where he
was the head of the research group responsible for target discovery
and pipeline expansion. At Gilead Sciences, he led Research and
Pharmacology teams for more than 15 years, achieving five INDs and
contributing to the advancement of approved cardiovascular drugs.
He earned his Ph.D. in Pharmacology from Tulane University, and
completed his post-doc at the National Academy of Sciences.
“I’m excited to join the Moonwalk team at a pivotal time as the
company advances its preclinical efforts to pioneer new insights
about epigenetic biology and engineering cell state,” said Dr.
Liles. “Having operated in cardiometabolic diseases, I appreciate
the role of epigenetics in the regulation of adipose and liver
tissue biology. We've seen the significant impact of current
cardiometabolic therapies, and I believe the future holds even
greater potential to yield novel mechanisms of action and improved
therapeutic profiles. Better elucidating this biology is a rich
area for new discoveries, and could represent a large therapeutic
opportunity.”
Moonwalk Cardiometabolic Advisory Board:
- Paul Cohen, M.D., Ph.D., Albert Resnick, MD Associate
Professor, Senior Attending Physician, and Head of the Weslie R.
and William H. Janeway Laboratory of Molecular Metabolism at the
Rockefeller University
- Silvia Corvera, M.D., Endowed Chair in Diabetes Research,
Professor, Program in Molecular Medicine, UMass Chan Medical
School
- Michael Czech, Ph.D., The Isadore and Fannie Foxman Professor,
Program in Molecular Medicine at UMass Chan Medical School
- Shingo Kajimura, Ph.D., Professor of Medicine, Harvard Medical
School, HHMI Investigator
- Rohit Loomba, M.D., MHSc, Chief, Division of Gastroenterology
and Hepatology, Director, UCSD MASLD Research Center
“We are fortunate to attract and collaborate with such a stellar
group of advisors, and I look forward to working with them to
advance the science and development of medicines that alleviate
these major conditions,” said Dr. Aravanis.
Moonwalk will be presenting data and providing an update at
future scientific meetings, including an oral presentation at
ObesityWeek 2024 and a poster presentation at AALSD 2024.
About Moonwalk Biosciences
Moonwalk Biosciences is a preclinical stage biotechnology
company pioneering new insights and medicines utilizing epigenetic
biology and AI. Its novel platform technology provides a complete
view of the epigenome in health and disease (EpiRead), with the
most advanced AI prediction of epigenetic targets and the broadest
set of epigenetic engineering tools (EpiWrite). Moonwalk is
advancing internal drug discovery programs with an initial focus in
cardiometabolic disease. Moonwalk has developed a differentiated
approach to mapping the epigenome of cellular states at the whole
genome, single cell resolution level, as well as proprietary
strategies for precise epigenetic engineering and perturbation to
discover and test therapeutic targets. The combination enables both
a novel discovery platform and a path to developing
modality-agnostic therapeutics. For more information, visit
www.moonwalk.bio.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240819252856/en/
Media Kimberly Ha KKH Advisors 917-291-5744
kimberly.ha@kkhadvisors.com